Navigation Links
Sosei Assigns AD 923 Assets to Pharmasol
Date:10/6/2009

TOKYO, October 6 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei R&D Ltd., its wholly owned UK subsidiary, has entered into an agreement to assign its rights to the assets of AD 923, an optimised, sublingual formulation of the opioid analgesic fentanyl for the treatment of cancer breakthrough pain, as well as to the device for drug administration to Pharmasol R&D Ltd. ("Pharmasol"), a privately held UK company.

The AD 923 development programme had previously entered Phase III clinical trials in Europe. However, due to the changes in regulatory environment, restructuring of Sosei R&D business operation, the programme had been halted.

Based on the present agreement Sosei R&D will receive payments from Pharmasol based on revenues arising from the commercialization of these assigned assets.

Editor's notes:

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About Pharmasol

Pharmasol Corporation engages in the contract manufacturing, packaging, and warehousing of aerosols, liquids, gels, and lotions for the health care and cosmetics industries. It also offers consultancy services, including research and development, purchasing, and marketing.

For further information about Pharmasol, please visit http://www.pharmasol.co.uk

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
5. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
6. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... and PUNE, India , January 24, ... by Allied Market Research, titled, "Cold Chain Logistics Market ... Dairy & Frozen Dessert, Meat, Fish & Sea Food, ... and Industry Forecasts, 2014-2022," projects that the global cold ... by 2022, growing at a CAGR of 16% (2016 ...
(Date:1/24/2017)... LONDON , January 24, 2017 Analysis ... End User Liquid Biopsies - our new study reveals ... biopsy market heading? If you are involved in this sector you ... you the potential revenues streams to 2027, assessing data, trends, opportunities ... ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017   ... in the engineering and industrialization of biology to improve the ... that it has entered into a definitive agreement to acquire ... clinical-stage company and pioneer in the development of AdenoVerse™ gene ... expand upon GenVec,s expertise in adenoviral vectors and cGMP drug ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... changes during the Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). ... health insurance coverage. Mainly, people are witnessing higher deductibles, rising premiums, and few ...
(Date:1/24/2017)... ... 2017 , ... i2i Population Health, a national leader in population health management ... “Cary’s broad financial background is an excellent fit for i2i,” says Justin Neece, president. ... skills we need to take the company to the next level of growth.” ...
(Date:1/24/2017)... ... 24, 2017 , ... Learn to use popular brainwave and heart rhythm equipment ... Course offered by Dr. Carol Francis at PVNET on Sundays in February and March ... hands-on experiences. , Dr. Carol Francis shows business owners, parents, athletes, students ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s ... its annual Solutions Series of webinars will start January 31 with a session ... number of current health and benefits topics, including employee engagement, pricing transparency, population ...
(Date:1/24/2017)... ... ... Bellus Medical, a leader in medical aesthetics, today announced that Marek Dobke, M.D., ... will provide physician oversight for in-house clinical studies and hands-on device training, among other ... Professor of Surgery at UC San Diego Health and is a board certified plastic ...
Breaking Medicine News(10 mins):